← Leaderboards
John Langenfeld
Univ Of Med/Dent Nj-R W Johnson Med Sch
$3,679,743
Attributed
$3,679,743
Total exposure
2
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1M · FY2018–22$2M$1.5M$1M$500K$0
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$3,679,743 · 2
By mechanism
R01$3,209,133 · 1
K22$470,610 · 1
Top collaborators
No co-investigators on record.
Most similar at Univ Of Med/Dent Nj-R W Johnson Med Sch
Same institution · by research overlap
- Alexey G. Ryazanov$7,737,698
- James Q Zheng$14,531,635
Others in their field
Top investigators on “Bone Morphogenetic Proteins”
- Marlene Rabinovitch · Stanford University$21,709,813
- John A Kessler · Northwestern University$15,344,538
- Kristina I Bostrom · University Of California Los Angeles$15,121,244
- Akiko Hata · University Of California, San Francisco$14,378,243
- Martin M Matzuk · University Of Missouri-Columbia$13,743,367
- Mary C Mullins · University Of Pennsylvania$10,606,462
Research focus
Bone Morphogenetic ProteinsAngiogenesisCancer CellCellsPharmaceutical ChemistryComputational BiologySignaling ProteinPharmaceutical PreparationsMalignant NeoplasmsLeadBiologyMetabolicReceptorMouse ModelMalignant Neoplasm Of LungMitochondriaPathway InteractionsCancer Cell LineCancer SurvivalDown-RegulationBone Morphogenetic Protein ReceptorsCrystallographyCancer TherapyCell Death
Grant awards (13)
Determining the mechanisms by which bone morphogenetic protein inhibition promotes survival/neurogenesis and to trigger AMPK hyperactivation that includes neuronal and cancer death cell$391,156
R01 · FY2022 · CA · contact PI
Developing bone morphogenetic receptor II inhibitors for the treatment of cancer$356,439
R01 · FY2022 · CA · contact PI
Developing bone morphogenetic receptor II inhibitors for the treatment of cancer$201,477
R01 · FY2022 · CA · contact PI
Targeting BMP type 2 receptor for the treatment of breast cancer.$63,172
R01 · FY2022 · CA · contact PI
Developing bone morphogenetic receptor II inhibitors for the treatment of cancer$363,713
R01 · FY2021 · CA · contact PI
Determining the effects of bone morphogenetic protein receptor 2 (BMPR2) inhibition on neural stem cell neurogenesis and regulation of energy homeostasis in Alzheimerâs disease and cancer$389,236
R01 · FY2020 · CA · contact PI
Developing bone morphogenetic receptor II inhibitors for the treatment of cancer$363,713
R01 · FY2020 · CA · contact PI
Developing bone morphogenetic receptor II inhibitors for the treatment of cancer$363,713
R01 · FY2019 · CA · contact PI
Developing bone morphogenetic receptor II inhibitors for the treatment of cancer$352,801
R01 · FY2019 · CA · contact PI
Developing bone morphogenetic receptor II inhibitors for the treatment of cancer$363,713
R01 · FY2018 · CA · contact PI
THE ROLE OF A BONE MORPHOGENETIC PROTEIN IN LUNG CANCER$156,870
K22 · FY2004 · CA
THE ROLE OF A BONE MORPHOGENETIC PROTEIN IN LUNG CANCER$156,870
K22 · FY2003 · CA
THE ROLE OF A BONE MORPHOGENETIC PROTEIN IN LUNG CANCER$156,870
K22 · FY2002 · CA